POTS (postural orthostatic tachycardia syndrome): diagnosis and management

What POTS is

POTS (postural orthostatic tachycardia syndrome) is a chronic disorder of the autonomic nervous system in which the heart rate rises by ≥30 beats per minute within ten minutes of standing — without a significant drop in blood pressure — producing symptoms lasting at least three months. The defining clinical hallmark is that symptoms are worse upright and better lying flat.

The typical patient in Australian general practice is a young woman aged 15–50 who has spent months, sometimes years, being told her dizziness, fatigue, racing heart, brain fog, and exercise intolerance are due to anxiety or deconditioning. The Australian POTS Foundation estimates the diagnostic delay from symptom onset to confirmed diagnosis is four to seven years.

Post-COVID-19 has substantially increased the number of people presenting with POTS. An estimated 30–80% of patients with long COVID meet POTS diagnostic criteria, making it one of the most common post-COVID syndromes managed in general practice. Since 2020, POTS incidence has risen approximately 5–10 fold in younger adults.

An estimated 0.2–1.0% of the Australian population live with POTS — potentially 55,000–250,000 people. Around 80% are female.

POTS is treatable. A structured approach combining fluid and salt loading, compression garments, and graduated recumbent exercise reconditioning produces significant symptom improvement in the majority of patients. The challenge is recognition — and a simple ten-minute active stand test in the consulting room can make the diagnosis.

A. Core clinical — the AU general-practice framework

Who presents with POTS

The typical presentation in general practice:

• Female, age 15–50 — men and older adults are also affected but less commonly
• Onset post-viral — following COVID-19, Epstein–Barr virus, influenza, enterovirus, or parvovirus
• May have joint hypermobility — hypermobile Ehlers–Danlos syndrome (hEDS) occurs in 20–40% of POTS cases; Beighton score ≥5/9 in adults suggests generalised hypermobility
• History of reduced exercise tolerance, heat intolerance, near-fainting on standing, showering, or prolonged queuing
• Comorbid migraine, anxiety, irritable bowel syndrome, or chronic fatigue — these coexist rather than exclude POTS

History

Therapeutic Guidelines — Autonomic Disorders and the Heart Rhythm Society Expert Consensus identify the following cardinal symptoms:

• Light-headedness or pre-syncope on standing — most common presenting complaint
• Palpitations or racing heart when upright
• Fatigue — often profound, with post-exertional worsening
• Brain fog — difficulty concentrating, memory impairment, slowed processing
• Exercise intolerance disproportionate to apparent deconditioning
• Headache, particularly orthostatic or migraine-type
• Nausea, bloating, early satiety (gastrointestinal dysmotility)
• Visual blurring, “greyout,” or tunnel vision on standing
• Acrocyanosis — purple discolouration of dependent feet and legs when upright
• Heat intolerance and sweating dysregulation
• Sleep disturbance

Ask specifically whether symptoms are worse standing and better lying flat — this orthostatic pattern is the key discriminating feature.

Ask about recent viral illness, particularly COVID-19 within the prior two years; prolonged bed rest or hospitalisation; recent weight loss or dietary restriction; and new medications started near symptom onset (SSRIs, diuretics, vasodilators). Document caffeine, alcohol, daily fluid, and dietary salt intake.

Examination

• Height, weight, BMI, and hydration
• Beighton hypermobility score (≥5/9 in adults raises hEDS suspicion — thumb to forearm, little finger hyperextension, elbow/knee hyperextension, palms flat on floor)
• Skin findings — acrocyanosis or livedo reticularis on dependent limbs after prolonged standing, dermographism (mast cell activation overlap), skin hyperextensibility
• Cardiovascular — listen for murmur; mitral valve prolapse is more prevalent in POTS
• Neurological — typically normal; small-fibre neuropathy requires specialist assessment

The active stand test

The CSANZ Position Statement and the Heart Rhythm Society 2015 consensus support the active stand test as the in-clinic first-line diagnostic procedure:

1. Patient lies supine for 5 minutes; measure heart rate and blood pressure 2–3 times and take the average.
2. Patient stands.
3. Measure heart rate and blood pressure at 1, 3, 5, and 10 minutes of standing.
4. Positive for POTS: sustained heart-rate rise ≥30 bpm (≥40 bpm in adolescents 12–19) from supine baseline, without a blood pressure drop ≥20/10 mmHg (which would indicate orthostatic hypotension, a separate condition).

Keep a chair nearby. If the patient cannot safely complete ten minutes standing, record the maximum duration and the heart-rate trend. Document exact readings with timestamps.

If the active stand test is inconclusive but clinical suspicion remains high, refer for a formal tilt-table test (MBS item 11516, specialist-billed).

Investigations

Per eTG — Autonomic Disorders:

• FBC — exclude anaemia as contributing cause
• U&E, eGFR — renal function and baseline electrolytes
• Ferritin and iron studies — iron deficiency worsens autonomic and fatigue symptoms; target ferritin >50 mcg/L in this context
• TSH — exclude hypo- and hyperthyroidism
• Fasting glucose and HbA1c — exclude diabetic autonomic neuropathy
• B12 and folate
• Vitamin D
• ANA, ENA, Sjögren’s panel if autoimmune features

Cardiac: 12-lead ECG (MBS item 11700; exclude pre-excitation, inappropriate sinus tachycardia). Transthoracic echocardiogram (MBS item 55135) if structural cardiac disease is suspected.

B. Differential diagnosis — ruling out POTS mimics

POTS is a diagnosis of exclusion. Key differentials:

Condition	Distinguishing feature
Orthostatic hypotension	Blood pressure drops ≥20/10 mmHg on standing; no primary tachycardia; different mechanism
Vasovagal syncope	Episodic reflex syncope with prodrome; not sustained tachycardia; tilt-table provocation
Inappropriate sinus tachycardia (IST)	Resting HR >100 bpm not purely postural
Hyperthyroidism	TSH suppressed; weight loss, tremor; treat the thyroid
Anaemia	Low haemoglobin explains symptoms; corrects with iron or B12 repletion
Anxiety disorder	Episodic, hyperventilation pattern — but POTS and anxiety frequently coexist; POTS is often wrongly labelled anxiety alone
ME/CFS	Post-exertional malaise dominant; significant overlap with POTS
Phaeochromocytoma	Episodic hypertension, headache, sweating; urinary metanephrines elevated
Eating disorder	Hypovolaemia from restriction; resolves with nutritional rehabilitation
Drug-induced tachycardia	Recent SSRI initiation, diuretics, vasodilators; resolves on cessation

NPS MedicineWise emphasises that POTS frequently coexists with anxiety disorders, irritable bowel syndrome, and migraine — these comorbidities do not exclude POTS and should be managed alongside it.

The POTS + hypermobile EDS + mast cell activation syndrome triad is well-recognised in specialist literature and occurs in 20–40% of POTS patients; if all three are suspected, haematology or immunology input may be needed alongside cardiology or autonomic neurology.

C. Management — lifestyle, reconditioning and pharmacotherapy

The cornerstone of POTS management is non-pharmacological. The Heart Rhythm Society 2015 Expert Consensus places lifestyle interventions first-line.

Fluid and salt loading

• 2–3 litres of fluid per day — water and electrolyte solutions (Hydralyte, Gastrolyte)
• 8–10 g salt per day via dietary intake and electrolyte supplements — unless hypertension or heart failure is present
• Salt and fluid loading increases plasma volume, reducing the compensatory tachycardia

Compression garments

• Waist-high compression stockings 30–40 mmHg — below-knee stockings provide insufficient venous return support for POTS; waist-high coverage is essential
• Abdominal binders add benefit for splanchnic venous pooling

Graduated exercise reconditioning

Fu et al. JACC 2010 demonstrated significant improvement in orthostatic tolerance with supervised recumbent-first reconditioning in POTS. The Levine/CHOP protocol:

• Begin with horizontal exercise — swimming, recumbent cycling, or rowing — to avoid orthostatic stress
• Three to four sessions per week, 30–45 minutes
• Add leg and core resistance training — calf pumps and squats support venous return
• Progress to upright exercise only once supine exercise is well tolerated for at least four to six weeks
• Target three to six months to meaningful functional improvement

For patients with ME/CFS overlap: use an energy-envelope and pacing approach — pushing through fatigue worsens post-exertional malaise and is counterproductive.

Practical behavioural adjustments

• Avoid prolonged standing — use sit-to-stand alternation, leg crossing, or calf pumping when upright
• Avoid hot environments, hot showers, and saunas
• Small frequent low-glycaemic index meals — reduces post-prandial splanchnic pooling
• Fixed sleep-wake schedule; elevate the head of the bed 10–15 cm
• Moderate caffeine (some patients find it helpful; others find it worsens palpitations — individualise)
• Reduce or avoid alcohol

Pharmacotherapy (specialist-initiated, mostly off-label)

In general practice, focus on optimising lifestyle and coordinating specialist referral. Pharmacotherapy for POTS in Australia is mostly off-label and initiated by cardiology or an autonomic specialist.

Per eTG — Autonomic Disorders and the AMH:

• Propranolol 10–40 mg twice daily (low dose, short-acting) — reduces sympathetic-overactivation tachycardia; PBS-listed for general use; first choice if trialling pharmacotherapy in general practice with specialist guidance
• Ivabradine 2.5–7.5 mg twice daily — selective sinus-node inhibitor without blood pressure lowering; useful if beta-blocker is poorly tolerated; TGA-approved for stable angina and heart failure; off-label for POTS
• Fludrocortisone 0.05–0.2 mg daily — mineralocorticoid; expands plasma volume; PBS Authority for Addison’s disease; off-label for POTS hypovolaemic phenotype
• Midodrine 5–10 mg three times daily — alpha-1 agonist; PBS-listed for orthostatic hypotension under specialist authority

Avoid anticholinergic antihistamines, tricyclic antidepressants (unless for migraine or neuropathic pain with specialist oversight), and alcohol.

Psychological and social support

Many patients have experienced years of diagnostic dismissal. Validating the diagnosis is itself therapeutic. Cognitive behavioural therapy addressing chronic-illness adjustment and anxiety comorbidity improves quality of life and coping. Refer via Mental Health Treatment Plan (MBS item 2715).

D. Australian operations

Specialist pathway

Suspected POTS warrants referral to cardiology or an autonomic specialist. Waiting lists are long in most states; GPs initiating first-line lifestyle interventions while awaiting specialist review is appropriate.

Long COVID Australia resources support clinicians and patients navigating post-COVID POTS. Multidisciplinary long-COVID clinics operating in NSW, VIC, QLD, and WA integrate POTS assessment and rehabilitation.

The Australian POTS Foundation maintains a clinician directory and patient support resources.

MBS and care planning

• Items 23, 36, 44, 45 — GP attendance; longer consult codes are appropriate given complexity
• GPCCMP items 965/967 — replaced GP Management Plan + Team Care Arrangement from 1 July 2025; use for coordinating allied health referrals (physiotherapy, dietitian, psychologist, occupational therapist)
• MBS item 2715 — Mental Health Treatment Plan; psychology referral
• MBS item 55135 — transthoracic echocardiogram
• MBS item 11700 — 12-lead ECG
• MBS item 11516 — tilt-table test (specialist-billed)
• MBS item 11600/11602 — Holter monitor if arrhythmia characterisation needed

PBS summary

• Propranolol — PBS general schedule (no Authority)
• Midodrine — PBS Authority required (specialist-prescribed for orthostatic hypotension)
• Fludrocortisone — PBS Authority for Addison’s disease; private prescription for off-label POTS use
• Ivabradine — PBS Authority for heart failure or chronic stable angina; off-label for POTS

Driving and employment

Austroads “Assessing Fitness to Drive” — recurrent syncope or presyncope with loss of awareness may trigger driving restrictions; assess case-by-case and document clearly.

For students and workers, document support needs: frequent seated breaks, water access, avoidance of prolonged standing, modified physical activity, flexible or home-based work arrangements. NDIS access may be available for severe and persistent functional impairment.

E. Special populations

Post-COVID POTS

This is now one of the most common POTS presentations in general practice. Long COVID Australia recognises POTS as a core long-COVID syndrome. Apply the same first-line approach — fluid, salt, compression, graduated reconditioning — with careful pacing to avoid post-exertional malaise. Refer to a long-COVID multidisciplinary clinic if available.

Adolescents

The diagnostic threshold in adolescents aged 12–19 is ≥40 bpm heart-rate rise on standing. POTS commonly presents in teenage girls following viral illness. School accommodations (frequent breaks, water, modified physical education, recumbent rest access), family education, and a school-compatible reconditioning plan are priorities.

Pregnancy

Most patients with POTS improve during the second trimester due to physiological haemodilution. Fluid and salt loading continue. Medication review is required — propranolol and fludrocortisone have limited pregnancy safety data; midodrine and ivabradine are generally avoided. Post-partum exacerbation is common; plan early review.

Hypermobile EDS overlap

Physiotherapy addressing core and lower-limb strength, joint stability, and venous return is particularly important. Pelvic floor and calf-strengthening exercises support autonomic regulation. Coordinate with rheumatology or clinical genetics for EDS management.

ME/CFS overlap

Patients with concurrent post-exertional malaise require pacing rather than conventional push-to-progress reconditioning. An energy-envelope approach — staying well within the point of symptom exacerbation — is the starting framework. Specialist ME/CFS services are available in most major Australian cities. HealthDirect Australia provides consumer-facing resources.

When to escalate

Refer to cardiology or autonomic specialist when:

• Diagnosis is uncertain after an active stand test
• Active stand test is positive but first-line lifestyle measures fail after three months
• Pharmacotherapy is being considered
• Recurrent syncope (loss of consciousness), not just presyncope — may require formal tilt-table assessment
• Suspected secondary causes: autoimmune disease, Sjögren’s syndrome, phaeochromocytoma, small-fibre neuropathy
• Significant functional impairment warranting NDIS or disability support
• Pregnancy with poorly controlled POTS

Refer same-day or to ED if: severe haemodynamic instability, syncope with injury, new neurological deficit, or suspected phaeochromocytoma crisis (paroxysmal severe hypertension with headache and sweating).

What this article is and is not

This is general health information drawn from Australian general practice resources — Therapeutic Guidelines, RACGP clinical resources, the CSANZ POTS Position Statement, NPS MedicineWise, and the Australian POTS Foundation — and international references including the Heart Rhythm Society 2015 Expert Consensus. It is not personal medical advice and does not create a doctor–patient relationship. Specific investigations, diagnoses, and treatments are determined with your own GP and treating specialists.

For Australian consumer resources: Australian POTS Foundation, Long COVID Australia, HealthDirect.

---

Sources cited

1. Heart Rhythm Society 2015 Expert Consensus — POTS (Sheldon RS et al.)
2. Australian POTS Foundation
3. Cardiac Society of Australia and New Zealand — POTS Position Statement
4. Therapeutic Guidelines — Autonomic Disorders
5. RACGP
6. NPS MedicineWise
7. Long COVID Australia — POTS pathway
8. Austroads — Assessing Fitness to Drive
9. HealthDirect Australia
10. Vernino S et al. POTS State-of-the-Art. Auton Neurosci 2021
11. Fu Q et al. JACC 2010 — POTS reconditioning trial
12. Raj SR. Mayo Clin Proc 2022 — POTS comprehensive review